Immunosuppressive Agents - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511242701

Publication Date:

November 28, 2024

Pages:

105

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Immunosuppressive agent: A medication that depresses or halts immune system activity. For example, immunosuppressive agents may be given to prevent the body from forming an immune response to an organ transplant or to treat a disease that is caused by an overactive immune system, such as rheumatoid arthritis.
The global market for Immunosuppressive Agents was estimated to be worth US$ 1310 million in 2023 and is forecast to a readjusted size of US$ 1874.3 million by 2030 with a CAGR of 4.6% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Immunosuppressive Agents, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Immunosuppressive Agents by region & country, by Type, and by Application.
The Immunosuppressive Agents market size, estimations, and forecasts are provided in terms of sales volume (Kiloton) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immunosuppressive Agents.
麻豆原创 Segmentation
By Company
Huadong Medicine
Fujisawa Pharmaceutical Co Ltd
Astellas
Roche
Novartis
North China Pharmaceutical Group
Segment by Type:
Cyclosporin
Tacrolimus
Everolimus
Sirolimus
Mycophenolic Acid
Segment by Application
Innate Immune Disease Treatment
Organ Transplant
Cancer Treatment
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Immunosuppressive Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Immunosuppressive Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Immunosuppressive Agents in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Immunosuppressive Agents Product Introduction
1.2 Global Immunosuppressive Agents 麻豆原创 Size Forecast
1.2.1 Global Immunosuppressive Agents Sales Value (2019-2030)
1.2.2 Global Immunosuppressive Agents Sales Volume (2019-2030)
1.2.3 Global Immunosuppressive Agents Sales Price (2019-2030)
1.3 Immunosuppressive Agents 麻豆原创 Trends & Drivers
1.3.1 Immunosuppressive Agents Industry Trends
1.3.2 Immunosuppressive Agents 麻豆原创 Drivers & Opportunity
1.3.3 Immunosuppressive Agents 麻豆原创 Challenges
1.3.4 Immunosuppressive Agents 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Immunosuppressive Agents Players Revenue Ranking (2023)
2.2 Global Immunosuppressive Agents Revenue by Company (2019-2024)
2.3 Global Immunosuppressive Agents Players Sales Volume Ranking (2023)
2.4 Global Immunosuppressive Agents Sales Volume by Company Players (2019-2024)
2.5 Global Immunosuppressive Agents Average Price by Company (2019-2024)
2.6 Key Manufacturers Immunosuppressive Agents Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Immunosuppressive Agents Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Immunosuppressive Agents
2.9 Immunosuppressive Agents 麻豆原创 Competitive Analysis
2.9.1 Immunosuppressive Agents 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Immunosuppressive Agents Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunosuppressive Agents as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cyclosporin
3.1.2 Tacrolimus
3.1.3 Everolimus
3.1.4 Sirolimus
3.1.5 Mycophenolic Acid
3.2 Global Immunosuppressive Agents Sales Value by Type
3.2.1 Global Immunosuppressive Agents Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Immunosuppressive Agents Sales Value, by Type (2019-2030)
3.2.3 Global Immunosuppressive Agents Sales Value, by Type (%) (2019-2030)
3.3 Global Immunosuppressive Agents Sales Volume by Type
3.3.1 Global Immunosuppressive Agents Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Immunosuppressive Agents Sales Volume, by Type (2019-2030)
3.3.3 Global Immunosuppressive Agents Sales Volume, by Type (%) (2019-2030)
3.4 Global Immunosuppressive Agents Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Innate Immune Disease Treatment
4.1.2 Organ Transplant
4.1.3 Cancer Treatment
4.1.4 Other
4.2 Global Immunosuppressive Agents Sales Value by Application
4.2.1 Global Immunosuppressive Agents Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Immunosuppressive Agents Sales Value, by Application (2019-2030)
4.2.3 Global Immunosuppressive Agents Sales Value, by Application (%) (2019-2030)
4.3 Global Immunosuppressive Agents Sales Volume by Application
4.3.1 Global Immunosuppressive Agents Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Immunosuppressive Agents Sales Volume, by Application (2019-2030)
4.3.3 Global Immunosuppressive Agents Sales Volume, by Application (%) (2019-2030)
4.4 Global Immunosuppressive Agents Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Immunosuppressive Agents Sales Value by Region
5.1.1 Global Immunosuppressive Agents Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Immunosuppressive Agents Sales Value by Region (2019-2024)
5.1.3 Global Immunosuppressive Agents Sales Value by Region (2025-2030)
5.1.4 Global Immunosuppressive Agents Sales Value by Region (%), (2019-2030)
5.2 Global Immunosuppressive Agents Sales Volume by Region
5.2.1 Global Immunosuppressive Agents Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Immunosuppressive Agents Sales Volume by Region (2019-2024)
5.2.3 Global Immunosuppressive Agents Sales Volume by Region (2025-2030)
5.2.4 Global Immunosuppressive Agents Sales Volume by Region (%), (2019-2030)
5.3 Global Immunosuppressive Agents Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Immunosuppressive Agents Sales Value, 2019-2030
5.4.2 North America Immunosuppressive Agents Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Immunosuppressive Agents Sales Value, 2019-2030
5.5.2 Europe Immunosuppressive Agents Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Immunosuppressive Agents Sales Value, 2019-2030
5.6.2 Asia Pacific Immunosuppressive Agents Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Immunosuppressive Agents Sales Value, 2019-2030
5.7.2 South America Immunosuppressive Agents Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Immunosuppressive Agents Sales Value, 2019-2030
5.8.2 Middle East & Africa Immunosuppressive Agents Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Immunosuppressive Agents Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Immunosuppressive Agents Sales Value
6.2.1 Key Countries/Regions Immunosuppressive Agents Sales Value, 2019-2030
6.2.2 Key Countries/Regions Immunosuppressive Agents Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Immunosuppressive Agents Sales Value, 2019-2030
6.3.2 United States Immunosuppressive Agents Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Immunosuppressive Agents Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Immunosuppressive Agents Sales Value, 2019-2030
6.4.2 Europe Immunosuppressive Agents Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Immunosuppressive Agents Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Immunosuppressive Agents Sales Value, 2019-2030
6.5.2 China Immunosuppressive Agents Sales Value by Type (%), 2023 VS 2030
6.5.3 China Immunosuppressive Agents Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Immunosuppressive Agents Sales Value, 2019-2030
6.6.2 Japan Immunosuppressive Agents Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Immunosuppressive Agents Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Immunosuppressive Agents Sales Value, 2019-2030
6.7.2 South Korea Immunosuppressive Agents Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Immunosuppressive Agents Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Immunosuppressive Agents Sales Value, 2019-2030
6.8.2 Southeast Asia Immunosuppressive Agents Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Immunosuppressive Agents Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Immunosuppressive Agents Sales Value, 2019-2030
6.9.2 India Immunosuppressive Agents Sales Value by Type (%), 2023 VS 2030
6.9.3 India Immunosuppressive Agents Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Huadong Medicine
7.1.1 Huadong Medicine Company Information
7.1.2 Huadong Medicine Introduction and Business Overview
7.1.3 Huadong Medicine Immunosuppressive Agents Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Huadong Medicine Immunosuppressive Agents Product Offerings
7.1.5 Huadong Medicine Recent Development
7.2 Fujisawa Pharmaceutical Co Ltd
7.2.1 Fujisawa Pharmaceutical Co Ltd Company Information
7.2.2 Fujisawa Pharmaceutical Co Ltd Introduction and Business Overview
7.2.3 Fujisawa Pharmaceutical Co Ltd Immunosuppressive Agents Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Fujisawa Pharmaceutical Co Ltd Immunosuppressive Agents Product Offerings
7.2.5 Fujisawa Pharmaceutical Co Ltd Recent Development
7.3 Astellas
7.3.1 Astellas Company Information
7.3.2 Astellas Introduction and Business Overview
7.3.3 Astellas Immunosuppressive Agents Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Astellas Immunosuppressive Agents Product Offerings
7.3.5 Astellas Recent Development
7.4 Roche
7.4.1 Roche Company Information
7.4.2 Roche Introduction and Business Overview
7.4.3 Roche Immunosuppressive Agents Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Roche Immunosuppressive Agents Product Offerings
7.4.5 Roche Recent Development
7.5 Novartis
7.5.1 Novartis Company Information
7.5.2 Novartis Introduction and Business Overview
7.5.3 Novartis Immunosuppressive Agents Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Novartis Immunosuppressive Agents Product Offerings
7.5.5 Novartis Recent Development
7.6 North China Pharmaceutical Group
7.6.1 North China Pharmaceutical Group Company Information
7.6.2 North China Pharmaceutical Group Introduction and Business Overview
7.6.3 North China Pharmaceutical Group Immunosuppressive Agents Sales, Revenue and Gross Margin (2019-2024)
7.6.4 North China Pharmaceutical Group Immunosuppressive Agents Product Offerings
7.6.5 North China Pharmaceutical Group Recent Development
8 Industry Chain Analysis
8.1 Immunosuppressive Agents Industrial Chain
8.2 Immunosuppressive Agents Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Immunosuppressive Agents Sales Model
8.5.2 Sales Channel
8.5.3 Immunosuppressive Agents Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Huadong Medicine
Fujisawa Pharmaceutical Co Ltd
Astellas
Roche
Novartis
North China Pharmaceutical Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.